use epigenet protein interact target
cancer initi outperform
initi coverag outperform rate
target price development-stag biotechnolog compani
constel use epigenet address prostat cancer well solid
tumor use protein-protein interact treat myelofibrosi
constel pharmaceut current two experiment clinic compound
develop one compound address prostat cancer
address myelofibrosi prostat cancer small molecul
design promot anti-tumor activ specif inhibit
address myelofibrosi small molecul inhibitor bet
compound current evalu phase ii clinic trial
estim could sale model
launch prostat cancer launch
myelofibrosi could result product sale billion
could gener product sale million
estim year-end expens increas
million million sg expens rose million million
oper loss increas million million
dilut ep expect neg turn posit
assum strategi constel fulli develop commerci
compound estim need rais approxim billion
fund program current estim launch
year
clinical-stag biopharmaceut
epigenet discov develop
patient
cancer associ abnorm gene
express drug resist
expertis
analyst certif import disclosur see disclosur
base outlook constel could launch first two
potenti drug estim revenu could increas
billion
estim oper loss increas next five year
compound-annual-growth-rate compani turn profit
revenu start meaning off-set loss
dilut ep expect neg
turn posit
estim sell price experiment product
low constel gain fda approv indic
model market penetr rapid
estim would signific upsid
compani constel stage develop
pre-approv primarili focu potenti futur revenu
valu base expect constel
launch first product next six year total revenu
increas billion howev case
development-stag compani estim carri
degre risk
prostar data
orion- data earli
data
ind
acknowledg possibl signific downsid
estim due inher risk drug develop
worst case constel stock could littl
appli biotech group averag price-to-sal ratio risk-discount revenu estim million
billion discount arriv valu billion discount invest return six half year arriv
valu million per share
biggest risk product candid possibl gain fda approv therefor becom commerci product
gain fda approv risk includ manufactur secur favor price third parti reimburs
patient drug cost patient behavior physician adopt product maintain patent protect structur chang
tabl content
summari potenti near-term
anticip data releas regulatori
initi coverag development-stag
biotechnolog compani use epigenet address prostat cancer well
solid tumor use protein-protein interact treat myelofibrosi
outperform rate target price anticip constel
commerci development-stag drug prostat cancer
myelofibrosi
compani constel stage develop pre-approv
primarili focu potenti futur revenu valu base expect
constel launch first product next six year estim total
revenu increas billion howev case development-
stage compani estim carri degre risk
accord proprietari databas averag forward price-to-sal multipl
biotechnolog sector discount estim revenu billion
risk failur invest return arriv target price
howev acknowledg possibl signific downsid estim due
inher risk drug develop worst case constel
stock could littl valu
valuat methodolog compani depend development-stag
product meaning percentag estim futur earn base appli
industri price-to-earnings multipl price-to-earnings growth rate ratio price-to-sal multipl
estim futur earn revenu discount valu base
estim risk failur use biotechnolog group multipl deriv averag
multipl compani profit sever year exhibit defin
biotechnolog industri equal weight stock biotechnolog compani
posit earn
exhibit price-to-earn price-to-earnings price-to-earnings growth price-to-sal ratio calcul
base price group last day month consensu earn per share
estim forward year sourc data use calcul
databas compil maintain oppenheim co use estim factset price
quot servic
typic appli averag multipl futur estim revenu earn
determin discount rate base compani stage develop use risk
failur base phase develop publish tuft center studi
drug develop base data failur rate potenti drug phase
develop approxim progress phase ii develop
failur rate approxim progress phase develop
rate roughli final actual file approv food
drug administr failur rate
constel pipelin two experiment clinic therapi
three pre-clin candid first anticip commerci impact
result product sale would account
estim revenu phase ii clinic trial
calcul combin weight averag risk discount potenti revenu
summari appli biotech group averag price-to-sal ratio
risk-discount revenu million billion discount arriv
valu billion discount invest return six half year
arriv valu million per share
constel found academ leader field
epigenet constel early-stag epigenet compani multipl target
bet field epigenet demonstr import
chromatin-associ protein regul add remov recogn variou
chemic modif mark specif site chromatin mark play key
role determin whether gene epigenet regul often refer
writer add modif eras remov modif reader bind
chromatin focus develop novel tumor-
target immuno-oncolog therapi base pioneer research cancer
epigenet nearli decad experi field compani view
unparallel understand chromatin biolog modul gene express
constel translat insight advanc two lead clinic program
bet novel target cancer epigenet play central role
david alli phd co-found ltd constel
pharmaceut inc dr alli leader field chromatin biolog
professor head laboratori chromatin biolog rockefel univers
new york ny pioneer experiment theoret studi elucid
mechan post-transl modif histon regul function
chromatin open new era chromatin biolog understand genom
function current serv member scientif advisori board upstat
reinberg phd co-found constel dr reinberg world-recogn
leader field mammalian transcript regul chromatin dynam
epigenet regul current serv professor biochemistri molecular
pharmacolog new york univers school medicin numer advanc
field biolog detail public dr reinberg current serv
member nation academi scienc
yang shi phd co-found constel dr shi professor patholog
harvard medic school note leader field histon demethylas
discov character first member class enzym dr shi made
key contribut constel understand mechan implic
epigenet modif gene regul genet diseas
scienc epigenet
human genom compris approxim uniqu gene modif
dna sequenc mutat gene alter express function sometim
lead diseas howev gene express also regul modif
microstructur dna associ protein process refer
epigenet essenti regulatori process allow activ
suppress cell-typ specif gene express program cancer alter
epigenet compon independ drive cellular transform diseas
patholog epigenet provid instruct genet code
histon domin epigenet control point cancer
two major epigenet mechan direct modif dna
includ addit remov methyl group modif histon protein
associ dna dna methyl coval addit methyl group
dna base usual cytosin protein known dna methyltransferas dnmt
typic methyl dna repress gene express addit dna methyl
also divers group enzym modifi histon protein wrap dna
regul open close particular genom region transcript
machineri myriad type coval modif alter histon function includ
methyl acetyl phosphoryl ubiquityl citrulin other
howev two major mechan current focu epigenet drug
develop effort histon methyl acetyl modif
revers mutual exclus collect influenc expos
dna transcript machineri thu directli impact gene express
histon acetyl gener histon acetyl result looser associ
histon dna permiss gene transcript protein add
acetyl group known histon acetyl transferas hat oppos reaction
remov acetyl group caus tighter associ suppress gene express
protein remov acetyl group known histon deacetylas hdac drug
target hdac major focu oncolog drug develop effort
discuss detail
histon methyl gener histon methyl result tighter associ
histon dna suppress gene express protein add methyl
group known histon methyltransferas hmt oppos reaction
remov methyl group caus looser associ enhanc gene express
protein remov methyl group known histon demethylas
methyltransferas gene transcript suppressor small molecul
inhibitor histon methyltransferas catalyt subunit polycomb
repress complex highli potent transcript repressor complex
normal respons mainten specif gene express program
frequent dysregul either gain-of-funct mutat overexpress
number solid tumor hematolog cancer ezh dysregul lead alter
activ associ aggress cancer phenotyp
mutat non-hodgkin lymphoma certain sarcoma becom
oncogen driver
bet bromodomain control key oncogen immun fibrot pathway bromodomain
extra-termin bet famili four relat protein
brdt contain bromodomain protein motif bet protein promot open chromatin
thu posit regul gene transcript bet famili member often
necessari express myc oncogen transcript frequent dysregul
cancer recent data demonstr chemic inhibit bet myc-driven
tumor block myc express select induc cell death bet also control
immun signal block nfkb fibrosi block tgf- constel bet
inhibitor current evalu treatment patient b-cell
lysine-specif histon demethylas epigenet protein remov
methyl group demethyl lysin restudi histon reaction lead
epigenet gene silenc frequent implic suppress tumor
genentech wholli own divis roch
januari constel enter licens collabor agreement
genentech collabor agreement constel genentech conduct
three-year research collabor program discov valid certain epigenet
target discov develop compound suitabl clinic develop
bind modul target decemb genentech select three target
acquir exclus right respect target may genentech
termin effect august exclus right two three select
target revert back constel genentech target current target
part constel clinic preclin discoveri program
genentech paid constel million up-front payment collabor
agreement provid addit fund research activ research
collabor respect select genentech target collabor agreement
provid mileston payment futur sales-bas mileston royalti payabl
constel upon achiev specifi mileston sale target
genentech specif first licens product genentech agre pay
aggreg million certain preclin clinic mileston regulatori
approv sale mileston certain sale mileston date genentech
paid constel million achiev preclin mileston
respect one genentech target constel report receiv
mileston payment royalti year end decemb
three month end march genentech also oblig pay tier royalti
rang mid-singl digit low-teen percentag net sale licens
juli constel enter research develop commerci
agreement leukemia lymphoma societi ll agreement ll
agre provid fund develop compound target toward certain
tandem bromodomain-contain protein design research use
treatment lymphoma myelodysplast syndrom acut myelogen leukemia
multipl myeloma accord agreed-upon budget mileston
constel ll amend agreement april allow potenti altern
compound includ ll agre fund altern
compound june societi agre pay million toward cost
research program constel report march ll paid
million mileston expect would trigger remain million
achiev
summari potenti near-term product
constel pharmaceut current two experiment clinic compound
develop three preclin program one experiment clinic compound
address prostat cancer address myelofibrosi
address prostat cancer small molecul design promot anti-tumor activ
specif inhibit address myelofibrosi small
molecul inhibitor bet compound current evalu phase ii
clinic trial estim could sale
model launch prostat cancer launch
myelofibrosi detail expect drug
section report appendix current estim could
result product sale billion could result product
sale million
compani websit sec file
small molecul inhibitor histon methyltransferas catalyt
subunit compound current two phase ib/ii clinic studi
treatment prostat cancer advanc solid tumor detail inform cpi-
appendix
small molecul inhibitor bromodomain extra-termin bet
famili protein current evalu phase ii studi monotherapi
combin ruxolitinib market jakafi patient myelofibrosi mf
previous treat ruxolitinib investig
inhibitor detail inform appendix
second-gener inhibitor design address larger patient
popul beyond target first-gener inhibitor
preclin result impli may provid coverag first-
year inhibitor could expand address popul studi
show improv resid time target constel current evalu
ind-en studi plan initi phase clinic trial solid tumor and/or
hematolog malign
lysine-specif histon demethylas epigenet protein remov
methyl group demethyl lysin restudi histon constel current
evalu small molecul inhibitor preclin develop treatment
anticip data releas fda file
base constel current pipelin new entiti summar
expect data news releas exhibit
exhibit expect data news releas base compani inform
calcul base studi enrol rate compani websit press releas
base constel current pipelin new entiti summar
expect regulatori file exhibit
exhibit expect regulatori file base compani inform
calcul base studi enrol rate compani file websit press releas
present
product candidateindicationstudyexpect time prostat cancer phase tumor recommend phase ii dataphas ii dose escalationearli tumors/hem malignanciesphas ii candidateindicationstudyfilingexpect time outperform
manag board
continu next page
name salari bonusopt award stock award exercis option share own experi summary/ career highlightsjigar raythatha presid chief execut offic raythatha spent nearli year biotechnolog industri varieti busi function rejoin constel may jounc held role chief busi offic first employe jounc help build compani incept publicli trade research develop organ previous serv head corpor develop constel led busi develop strategi program allianc manag function prior constel mr raythatha work red abbey ventur partner initi kauffman fellow later princip final ventur partner earlier career mr raythatha held role increas respons kearney earn master busi administr columbia univers bachelor art biochemistri econom rutger univers emma reev chief financi offic reev global financ execut work healthcar year across pharmaceut medic devic bio-pharma compani prior join emma serv interim chief financi offic corpor control parexel intern respons aspect financi report account investor relat financi plan analysi previous emma held senior financ role major pharma compani includ novarti merck bristol-my squibb also chief financi offic two development-stag biotech compani aton pharma addit financ emma held senior posit number countri area market suppli chain manag research oper emma hold sc comput scienc imperi colleg univers london associ institut charter account england wale adrian senderowicz senior vice presid chief medic offic board-certifi medic oncologist train dr adrian senderowicz bring constel two decad experi life scienc princip investig multitud clinic trial solid hematolog tumor dr senderowicz signific regulatori expertis former clinic team leader food drug administr fda center drug evalu research cder divis drug oncolog product prior join constel dr senderowicz serv chief medic offic cerulean pharma help secur fast-track design compani lead clinic develop program two indic previous dr senderowicz held role increas respons ignyta inc sanofi oncolog astrazeneca plc began career investig nation cancer institut join fda cder brad prosek senior vice presid corpor develop prosek senior vice presid corpor develop join compani terrain biopartn llc advis support global set life scienc client transact corpor commerci strategi well execut previous brad spent year built compani market access strategi organ led transact team respons deal includ acquisit support compani pipelin growth led new corpor ventur build complementari infect prevent busi prior cubist mr prosek serv grow commerci oper market busi develop role work health econom reimburs strategi consult covanc unit state europ robert sim phd senior vice presid research sim join found scientist nearli year experi chromatin biolog transcript dr sim help establish constel industry-lead epigenet platform dr sim led discoveri translat effort novel bet bromodomain inhibitor current phase clinic develop hematolog malign team notabl work along other field includ discoveri bet bromodomain inhibit silenc express myc oncogen dr sim author scientif public top-tier journal includ scienc natur cell receiv ph cellular molecular biolog univers texa austin complet postdoctor train umdnj-robert wood johnson medic school new york univers school medicin patrick trojer phd senior vice presid franchis head translat scienc trojer involv foundat constel earli join compani found scientist held multipl posit increas respons constel among mani achiev dr trojer drove constel program lead clinic launch current ph clinic trial lymphoma dr trojer intern recogn expertis chromatin biolog control gene transcript dr trojer author dozen scientif public frequent lectur epigenet space complet postdoctor studi nyu medic school dr danni reinberg laboratori prior receiv ph protein biochemistri molecular biolog microbiolog leopold franzen univers innsbruck austria karen valentin chief legal offic gener valentin began serv chief legal offic gener counsel juli prior join constel ms valentin serv chief legal offic gener counsel agenu inc publicli trade immune-oncolog compani septemb juli serv vice presid gener counsel agenu inc januari septemb prior join agenu inc ms valentin associ biotechnolog practic palmer dodg llp lock lord ms valentin current presid member board director northeast chapter associ corpor counsel ms valentin hold neurosci colgat univers receiv boston univers school law brenda sousa senior vice presid human resourc oper brenda sousa join constel vice presid human resourc constel march prior join constel ms sousa vice presid human resourc oper epix pharmaceut serv member global execut manag team focus develop implement busi strategi oper organiz develop us compani intern offic join epix director human resourc rk ventur spenc center women start-up ventur ultim purchas partner care prior human resourc career ms sousa work hospit industri focus sale market brenda join board career collabor initi serv chair employ advisori board brenda hold bachelor art degre univers massachusett comment constel experienc manag team relev biopharmaceut experi
board directorsagedirector salaryopt award stock award exercisbl option share own affiliation/car highlightsmark goldsmith ph found presid ceo director revolut goldsmith ph serv member board director sinc juli dr goldsmith presid chief execut offic director revolut medicin drug discoveri develop compani sinc novemb dr goldsmith previous partner third ventur third ventur capit firm march ventur partner third march dr goldsmith previous serv presid chief execut offic constel interim execut chairman june march dr goldsmith serv presid chief execut offic biotechnolog compani may june board director may septemb dr goldsmith also serv presid chief execut offic nurix inc drug discoveri compani may octob dr goldsmith also serv board director variou privat biotechnolog compani dr goldsmith serv chief execut offic chairman cogentu pharmaceut inc biotechnolog compani file petit bankruptci chapter unit state bankruptci code enter privat sector dr goldsmith led medic research laboratori gladston institut virolog immunolog practic medicin faculti school medicin univers california san francisco san francisco gener hospit consult lead pharmaceut biotechnolog compani dr goldsmith hold princeton univers ph microbiolog immunolog univers california san francisco jigar raythatha presid chief execut offic raythatha spent nearli year biotechnolog industri varieti busi function rejoin constel may jounc held role chief busi offic first employe jounc help build compani incept publicli trade research develop organ previous serv head corpor develop constel led busi develop strategi program allianc manag function prior constel mr raythatha work red abbey ventur initi kauffman fellow later princip final ventur partner earlier career mr raythatha held role increas respons biogen kearney earn master busi administr columbia univers bachelor art biochemistri econom rutger univers jame audia ph execut director chicago biomed jim audia current serv execut director chicago biomed consortium collabor effort northwestern univers univers chicago univers illinois-chicago focus enhanc biomed innov greater chicago area join cbc nearli seven-year tenur chief scientif offic oversaw success evolut compani effort strong scientif base robust portfolio clinical-stag asset pre-clin program dr audia join constel januari follow highli product career drug discoveri compani held sever key leadership role tenur lilli distinguish lilli scholar highest level compani scientif ladder made semin technic strateg contribut lilli drug pipelin cours career dr audia scientif work contribut develop candid includ transform contribut treatment alzheim diseas discoveri first gamma secretas inhibitor industry-lead beta secretas inhibitor dr audia name inventor issu patent publish present extens receiv ph organ chemistri univers south carolina postdoctor train yale univers join lilli dr audia current serv scientif advisor tau consortium rainwat foundat anthoni evnin ph evnin venrock ventur capit firm sinc current serv board aveo pharmaceut inc infin pharmaceut inc pharmo corpor well number privat compani dr evnin truste efel univers truste jackson laboratori truste emeritu princeton univers member board overs manag memori sloan-kett cancer center dr evnin hold ph chemistri massachusett institut technolog princeton univers peter svennilson manag founder column year experi corpor financ invest bank ventur capit founder partner three crown capit lead backer new gener us biotechnolog compani help found compani rosetta tercica somalog past year help financ develop biotech compani includ tularik sunesi infin aveo rinat fiveprim current board director biopharmaceut immun design gritston serv board sever biotechnolog compani includ chairman chairman rosetta somalog found three crown capit associ manag director european invest bank origin nomura secur london current truste institut advanc studi princeton new jersey robert tepper third tepper co-found third ventur serv dr tepper work activ portfolio compani shape scientif strategi capac dr tepper work cso constel april octob prior join third ventur dr tepper presid millennium pharmaceut co-found cell genesys/abgenix dr tepper serv adjunct faculti member harvard medic school massachusett gener hospit advisori board member sever lead health care institut includ healthcar center person genet medicin tuft medic school member research advisori council massachusett gener hospit comment constel board primarili compos repres ventur commun believ board current one independ member outperform
constel pharmaceut current reliant third-parti contract manufactur
preclin clinic product candid
constel revenu estim revenu launch
first product estim occur base outlook
constel could launch first two potenti drug estim revenu
could increas billion
estim year-end expens increas million
million sg expens rose million million oper loss
increas loss million loss million
assum constel fulli develop commerci compound
without addit partner strateg investor estim oper loss
increas next five year compound-annual-growth-rate model compani
turn profit revenu start meaning off-set loss estim
oper incom million scenario sg expens
increas averag per year next five year
respect line industri averag percentag product sale
dilut ep expect neg turn posit
estim constel oper cash flow neg
neg oper cash flow expect off-set financ
activ assum strategi constel fulli develop
commerci compound estim need rais approxim
billion fund program current estim launch
year anticip number would meaning
reduc constel use acceler approv pathway fda expect
sourc fund could result partnership equiti invest
howev model debt
estim suffici cash fund develop
program estim constel need approxim
billion addit cash
believ success next six year highli
depend fda approv launch current experiment clinic
compound
biggest risk product candid possibl gain fda approv
therefor becom commerci product gain fda approv
risk includ manufactur secur favor price third parti
reimburs patient drug cost patient behavior physician adopt product
maintain patent protect structur chang healthcar market
addit stock somewhat limit float could exacerb stock price volatil also
calcul approxim share own ventur capitalist
could period increas liquid volatil stock
convers estim sell price experiment product low
constel gain fda approv indic model market
penetr rapid estim would signific upsid
follow exhibit provid histor project incom statement exhibit
balanc sheet exhibit cash flow exhibit statement along product detail
experiment therapi exhibit exhibit
exhibit incom statement histor estim
constel pharmaceut nasdaq-cnst oppenheim co incom statement leah rush cann thousand except per share product licens contract good marginnmnmnmnmnmnmnmnmnmnminterest incom incom per per share dilut share share compani data oppenheim co estimatesaddit inform avail upon request constel pharmaceut
exhibit balanc sheet histor estim
constel pharmaceut nasdaq- oppenheim co balanc sheet leah rush cann thousand except per share asset restrict prepaid expens current long-term stockhold equitycurr liabil account current portion long-term debt net prefer stock tranch prefer stock warrant defer rent net current acur current current long-term equiti prefer common addit paid-in accumul comprehens accumul deficit/retain stockhold liabil compani data oppenheim co estimatesaddit inform avail upon request outperform
exhibit flow histor estim
constel pharmaceut nasdaq-cnst oppenheim co statementleah rush cann thousand except per share flow oper net depreci properti stock-bas amortizatoin premium non-cash interest loss dispos properti chang leas incent chang fair valu adjust share-bas compens chang fair valu chang fair valu prefer stock tranch asset liabil prepaid liabil current long-term defer account accru cash provid oper flow invest activ purchas properti plant proce properti plant cash provid invest flow financ activ proce issuanc common proce issuanc convert proce issuanc payment debt issuanc payment tax indemnif payment repay reimburs expens proce issuanc employe stock proce exercis common stock cash provid financ exhang rate cash cash increas cash cash begin end cash cash flow per cash flow per share cash cash flow per cash flow per share compani data oppenheim co estimatesaddit inform avail upon request constel pharmaceut
exhibit histor estim
patient populationprost cancer prevel cancer front line cancer second line higher tumor size prostat cancer prevel cancer mcrpc front line cancer mcrpc second line higher tumor penetrationprost cancer cancer mcrpc front cancer mcrpc second line higher tumor treatedprost cancer prevel cancer mcrpc front line cancer mcrpc second line dosag mgprostat cancer prevel prostat cancer mcrpc front line prostat cancer mcrpc second line highersolid tumorspric per cours therapi cancer prevel cancer mcrpc front line cancer mcrpc second line thousand prostat cancer prevel cancer mcrpc front line cancer mcrpc second line us sale ex-u sale ww sale compani data oppenheim co estimatesaddit inform avail upon request outperform
exhibit histor estim
patient populationmyelofibrosi preval previous treat jakafi frontlin secondlin size myelofibrosi previous treat jakafi frontlin secondlin penetrationmyelofibrosi previous treat jakafi frontlin secondlin treatedmyelofibrosi frontlin secondlin dosag mg frontlin secondlin per cours therapi frontlin secondlin price thousand myelofibrosi frontlin secondlin us sale sale ww sale compani data oppenheim co estimatesaddit inform avail upon request constel pharmaceut
endnot refer exhibit
incid deriv nation cancer institut nci seer percentag expect metastat castrat resist base scher et al plo incid deriv nation cancer institut nci seer deriv nation cancer institut nci seer cell account approxim rcc myeloprolif disord myelofibrosi zimmerman et al ajmc mari number patient treat jakafi estim opco jay olson treat per year use xtandi comparitor mehr ajmc estim annual therapi support jakafi price outperform
small molecul design promot anti-tumor activ specif
inhibit histon methyltransferas catalyt subunit polycomb
repress complex suppress target gene express
current evalu two phase ib/ii clinic trial one combin therapi
ar androgen receptor splice variant inhibitor prostat cancer prostar
trial second combin immun checkpoint inhibitor solid tumor
orion- trial evalu studi context prevent
current evalu combin ar inhibitor prostat
cancer immun checkpoint inhibitor solid tumor
trial patient oral administ mg dose three time per
day prostar trial patient oral administ abirateron acet
enzalutamid orion- subject intraven administ ipilimumab
still experiment therapi therefor establish price
estim potenti price annual cours therapi base
current price xtandi prostat cancer howev pure oppenheim
co estim provid strategi price
phase patient b-cell lymphoma
april constel initi first human open-label sequenti dose
escal expans phase studi monotherapi patient
progressive/relaps lymphoma trial includ patient dose-escal
portion trial ten expans portion patient dose-escal portion
trial receiv dose mg continu twice
daili dose basi constel complet studi demonstr
clinic single-ag activ well toler two partial respons
one long-term sp
constel pharmaceut current evalu two phase ib/ii clinic
trial combin therapi ar inhibitor prostat cancer immun
checkpoint inhibitor solid tumor
prostar phase ib/ii male patient metastat castrat
constel pharmaceut current sponsor two-arm open label phase ib/ii
clinic trial refer prostar trial male patient mcrpc
previous progress treatment either abirateron acet enzalutamid
elig patient previous progress treatment abirateron acet
treat combin enzalutamid elig patient
previous progress treatment enzalutamid treat combin
abirateron acet patient receiv mg dose three
time per day combin either abirateron acet enzalutamid
cohort patient given lower dose twice per day
combin fda-approv cytochrom enzym inhibit co-med
boost exposur either abirateron acet enzalutamid
cohort may escal higher dose twice per day
constel plan enrol patient phase ib portion trial aim
establish safeti pharmacokinet pharmacodynam maximum toler dose
recommend phase ii dose agent phase ii trial
constel assess respons rate primari endpoint reduct
circul tumor cell convers initi studi decemb aim
demonstr proof concept prostar studi success
constel plan initi pivot phase studi combin
enzalutamid abirateron acet treatment mcrpc
orion- phase ib/ii patient advanc solid tumor
constel pharmaceut current sponsor phase ib/ii multi-cent open-
label basket studi combin ipilimumab pembrolizumab
treatment patient solid tumor previous progress treatment
immun checkpoint inhibitor inhibit program death-ligand
program cell death protein similar prostar trial elig patient
receiv mg dose three time per day combin ipilimumab
pembrolizumab constel explor use fda-approv
cytochrom enzym inhibit co-med boost exposur lower
dose certain cohort patient trial primari endpoint
phase ib trial establish maximum toler dose recommend phase ii
dose agent constel aim establish safeti
pharmacokinet maximum toler dose recommend phase ii dose
combin earli plan initi phase ii portion trial thereaft
primari endpoint phase ii portion trial evalu object
respons defin complet respons partial respons per recist criteria
constel initi studi januari
base analysi patent appendix
 conclud patent protect expir
base current clinic develop program believ address
market therapi patient metastat castrate-resist prostat cancer
base data nation cancer institut nci estim mcrpc
current affect patient us exhibit
exhibit histor data data obtain nci seer databas estim preval preval
data adjust estim yearli incid death opco
approv us estim enter mcrpc market
market share front-lin set market penetr relaps
set estim achiev market penetr respect
market exhibit
exhibit penetr rate estim calcul number patient treat given year estim incid
preval opco
size prostat cancer prevel cancer mcrpc front line cancer mcrpc second line higher tumor penetrationprost cancer cancer mcrpc front cancer mcrpc second line higher outperform
sale estim base market penetr estim mcrpc
set averag price per cours therapi assum averag
durat therapi month estim world-wide sale
increas billion howev pure estim constel
commun strategi price us exhibit
exhibit estim world-wide sale grow billion
treatedprost cancer prevel cancer mcrpc front line cancer mcrpc second line per cours therapi cancer prevel cancer mcrpc front line cancer mcrpc second line thousand prostat cancer prevel cancer mcrpc front line cancer mcrpc second line us sale ex-u sale ww sale compani data oppenheim co estimatesaddit inform avail upon request constel pharmaceut
small molecul inhibitor bromodomain extra-termin bet famili
protein current evalu phase ii studi monotherapi
combin ruxolitinib market jakafi patient myelofibrosi mf
previous treat ruxolitinib investig inhibitor
current evalu patient myelofibrosi
ruxolitinib administ oral
still experiment therapi therefor establish price
estim potenti price annual cours therapi base
current price jakafi myelofibrosi howev strictli estim
constel pharmaceut provid strategi price
favor pharmacokinet
pharmacodynam profil well overal respons rate rang dose
maximum toler dose studi activ establish nfkb-driven
phase patient progress lymphoma
septemb constel pharmaceut initi first human open-label
sequenti dose escal expans studi patient progress
lymphoma total patient treat administ daili two
week follow one week treatment primari endpoint trial
establish safeti singl agent evalu frequenc dose-
limit toxic associ treatment day maximum
toler dose identifi mg daili
pharmacodynam chang clinic activ observ rang dose
maximum toler dose
phase patient hematolog malign
juli constel initi open-label sequenti dose escal studi
patient hematolog malign previous treat acut leukemia
myelofibrosi total patient includ studi
administ daili two week follow one week treatment primari
endpoint trial establish safeti singl agent
evalu frequenc dose-limit toxic associ treatment cpi-
day well toler trial lead phase ii studi
without ruxolitinib patient myelofibrosi
phase patient previous treat multipl myeloma
juli constel pharmaceut initi open-label sequenti dose
escal expans studi patient previous treat multipl
myeloma total total patient treat administ daili two
week follow one week treatment primari endpoint trial
establish safeti singl agent evalu frequenc dose-
limit toxic associ treatment day well
toler trial
constel pharmaceut current evalu phase ii studi
monotherapi combin ruxolitinib patient myelofibrosi
previous treat ruxolitinib investig inhibitor
phase ii patient myelofibrosi
follow complet phase evalu cpi-
two-arm open-label phase ii clinic trial second-lin treatment patient
myelofibrosi elig patient either enrol combin arm
ruxolitinib monotherapi arm combin arm consist patient
diseas progress treat ruxolitinib remain ruxolitinib
treatment arm constel add patient ruxolitinib treatment
monotherapi arm consist patient diseas progress despit prior
treatment ruxolitinib certain patient elig treatment
ruxolitinib arm trial patient administ dose mg cpi-
per day may titrat mg maximum toler dose
phase trial patient lymphoma primari endpoint trial
reduct spleen size baselin measur mri week treatment
red blood cell transfus independ rate patient transfus depend
baselin patient-report symptom
constel plan initi proof concept consult
fda regard accept endpoint initi pivot clinic trial
may four evalu patient two combin arm
two mono-therapi arm four signific reduct spleen volum
measur mri symptom
independ achiev normal platelet level seriou advers
event studi may
improv patient
base analysi patent appendix conclud
patent protect expir
base current clinic develop program believ address
market therapi myelofibrosi patient base data nci
estim myelofibrosi current affect patient us exhibit
exhibit histor data data obtain nci seer databas estim preval preval
data adjust estim yearli incid death opco
patient populationmyelofibrosi preval previous treat jakafi frontlin secondlin size myelofibrosi previous treat jakafi frontlin secondlin outperform
approv us estim enter myelofibrosi market
market penetr estim achiev market
penetr line myelofibrosi treatment exhibit
exhibit penetr rate estim calcul number patient treat given year estim incid
preval opco
sale estim base market penetr estim myelofibrosi
set averag price per cours therapi assum averag
durat therapi month front line month therapi
relapsed/previ treat set estim world-wide sale
increas million howev pure oppenheim co
estim share strategi
price us exhibit
exhibit estim world-wide sale grow million
penetrationmyelofibrosi previous treat jakafi frontlin secondlin treatedmyelofibrosi frontlin secondlin dosag mg frontlin secondlin per cours therapi frontlin secondlin price thousand myelofibrosi frontlin secondlin us sale sale ww sale compani data oppenheim co estimatesaddit inform avail upon request constel pharmaceut
methodolog collect patent inform
identifi patent drug clinic trial approv
fda yet constel sec file search identifi assigne drug
key term drug name indic search us patent
trademark offic websit identifi constel patent narrow
patent claim patent identifi relat patent could
identifi determin expir patent protect origin patent relat
drug identifi twenti year file origin patent patent
protect expir addit patent identifi narrow indic
import caveat patent attorney
conclud key patent protect expir
identifi patent found uspto exhibit
exhibit patent data uspto
conclud key patent protect expir
identifi patent found uspto exhibit
patent date filedd modul methyl modifi enzym composit use thereof provid modul methyl modifi enzym composit use thereof provid modul methyl modifi enzym composit use thereof provid modul methyl modifi enzym composit use thereof provid modul methyl modifi enzym composit use thereof provid modul methyl modifi enzym composit use thereof provid modul methyl modifi enzym composit use thereof provid modul methyl modifi enzym composit use thereof provid modul methyl modifi enzym composit use thereof provid modul methyl modifi enzym composit use thereof provid herein uspto constel pharmaceut
exhibit patent data uspto
patent date filedd present invent relat compound use inhibitor one histon demethylas invent also provid pharmaceut accept composit compris compound present invent method use said composit treatment variou present disclosur relat crystallin form acetamid use inhibitor bromodomain-contain protein present disclosur also provid pharmaceut accept composit compris crystallin form method use said composit treatment variou present invent relat compound use inhibitor bromodomain-contain protein invent also provid pharmaceut accept composit compris compound present invent method use said composit treatment variou disord present invent relat compound formula formula ii salt thereof wherein formula formula ii valu defin herein composit use thereof compound use inhibitor cbp present invent relat compound use inhibitor bromodomain-contain protein invent also provid pharmaceut accept composit compris compound present invent method use said composit treatment variou disord present invent relat compound use inhibitor bromodomain-contain protein invent also provid pharmaceut accept composit compris compound present invent method use said composit treatment variou present invent relat compound formula salt thereof wherein valu defin specif composit use thereof compound use inhibitor histon demethylas also includ pharmaceut accept composit compris compound present invent method use said composit treatment variou present invent relat compound use inhibitor bromodomain-contain protein invent also provid pharmaceut accept composit compris compound present invent method use said composit treatment variou disord present invent relat compound use inhibitor bromodomain-contain protein invent also provid pharmaceut accept composit compris compound present invent method use said composit treatment variou present invent relat compound use inhibitor bromodomain-contain protein invent also provid pharmaceut accept composit compris compound present invent method use said composit treatment variou present invent relat compound use inhibitor bromodomain-contain protein invent also provid pharmaceut accept composit compris compound present invent method use said composit treatment variou present invent relat compound use inhibitor bromodomain-contain protein invent also provid pharmaceut accept composit compris compound present invent method use said composit treatment variou disord uspto outperform
